Abstract: A method for analyzing fuselage profile based on measurement data of an aircraft, including: acquiring point-cloud data of an aircraft via a laser scanner; selecting point-cloud data of a fuselage component from the point-cloud data of the aircraft; based on a weighted locally optimal projection (WLOP) operator and Ll median curve-skeleton concept of point cloud, extracting a medial axis from the point-cloud data of the fuselage component; uniformly sampling the medial axis into a plurality of skeleton points; extracting a discrete point set of a cross-section contour of the fuselage component; performing circle fitting on the discrete point set to obtain a fitted circle and parameters thereof; calculating a deformation displacement measurement indicator ? of the cross-section of the fuselage component to evaluate cross-section contour of the fuselage.

Abstract: A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.

Abstract: A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.

Abstract: A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.

Abstract: A method of preventing, controlling or treating CMV infections with a vaccine comprising an immunologically effective amount of a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine.

Abstract: Herein provided are a model and method for a transgenic a bovidae having an TGF-?1 gene inserted into the bovidae genome and capable of expressing higher than normal levels of TGF-?1 in cardiac muscle.

Abstract: A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.

Abstract: A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.

Abstract: Herein provided are a model and method for a transgenic a bovidae having an TGF-?1 gene inserted into the bovidae genome and capable of expressing higher than normal levels of TGF-?1 in cardiac muscle.

Abstract: A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.

Abstract: A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.

Abstract: A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.

Abstract: A projector determines horizontal and vertical tilt angles. Using the tilt angles and the inherent properties of the projector, keystone correction corner points for the image can be computed. The keystone correction corner points can be used to perform keystone correction on the image.

Abstract: In general, the invention features methods of identifying and/or preparing a mammalian cell or a cell population (e.g., bovine or porcine cells) for use in cloning procedures or regenerative cell procedures using expression of one or more of the epigenetic markers, IGF2, p57, and NNAT.

Abstract: A projector determines horizontal and vertical tilt angles. Using the tilt angles and the inherent properties of the projector, keystone correction corner points for the image can be computed. The keystone correction corner points can be used to perform keystone correction on the image.

Abstract: A projector determines horizontal and vertical tilt angles. Using the tilt angles and the inherent properties of the projector, keystone correction corner points for the image can be computed. The keystone correction corner points can be used to perform keystone correction on the image.

Abstract: We describe a weighted absolute difference based deinterlace method and apparatus. The deinterlace method and apparatus uses weighted absolute differences along different directions as means for interpolating pixel data using edge orientation detection. The apparatus includes a memory adapted to store a current and previous fields and predetermined portions of a future field of an input signal. A motion detector is adapted to detect motion between the future and previous fields. An interpolating circuit is adapted to generate a plurality of output pixels using a corresponding plurality of methodologies. And a switch is adapted to select between the plurality of output pixels responsive to the motion detector.

Abstract: We describe a keystone correction system and method. A vertical scalar vertically scales an input image and stores the results to a line buffer. A horizontal scalar retrieves the stored results from the line buffer and horizontally scales the stored results using the relatively small number of lines from the line buffer. The system repeats the vertically scaling, storing, and horizontal scaling until it processes all input image lines.

Abstract: An output pixel datum is produced from input pixel data by a method wherein the brightness levels of several input pixels closely associated coordinate-wise with the output pixel, are examined to determine whether a relatively less complex graphics-optimized scaling procedure, or a relatively more sophisticated video-optimized scaling procedure, should be carried out. In the second case, directional interpolation is performed with a plurality of directions, e.g., being considered to determine the direction of minimum brightness level gradient. A plurality of intermediate pixels, e.g., four, are produced, which are aligned perpendicularly to the minimum brightness level gradient direction, their brightness levels being determined from relevant input pixels using linear interpolation. The output pixel brightness level is determined from the intermediate pixels through the use of an appropriate filtering technique, e.g., polyphase FIR filtering.

Abstract: The invention is a method and apparatus for reducing noise in an image. The method and apparatus involves calculating a plurality of directional operators, comparing the directional operators to a predetermined threshold, and applying a filter responsive to the comparing. The method and apparatus computes the directional operators by taking a weighted sum of the absolute differences between a target pixel and its surrounding pixels. The comparison signals to the method or apparatus the existence of a line or edge. If the method or apparatus detects no edge or line, the method applies a smoothing or averaging filter. If the method or apparatus detects an edge or line, the method applies a median filter in the direction with a minimum directional difference.